Introduction
============

As one of the most common types of cancer that threat the health of women worldwide, breast cancer originates from breast epidermal tissues and has a high mortality rate ([@b1-or-43-06-1928]). The difficulty in clinical treatment of breast cancer has mainly been attributed to two aspects. First, breast cancer exhibits a higher risk of metastasizing to distant vital organs of the body compared with other solid tumors ([@b2-or-43-06-1928]). Second, the heterogeneity of breast cancer limits the development of targeted therapy ([@b3-or-43-06-1928]). According to the expression of the estrogen receptor (ER), progesterone receptor (PR) and HER2, breast cancer can be classified into two categories ([@b4-or-43-06-1928]). For the first category, at least one of these receptors is positive. Selective ER inhibitors, such as Tamoxifen, and PR inhibitors, such as Mifepristone, are widely used in the clinical treatment of ER-positive and PR-positive breast cancer ([@b5-or-43-06-1928]). For the clinical treatment of HER2-positive breast cancer, the potent monoclonal HER2 antibody Herceptin and its derivatives are the most efficient therapy ([@b6-or-43-06-1928]). Combinations of Herceptin with small-molecular drugs for the treatment of HER2-positive metastatic breast cancer have entered clinical trials, suggesting the advantages of combined medication ([@b6-or-43-06-1928]).

For the second category, triple-negative breast cancer (TNBC) lacks the expression of ER, PR or HER2. According to statistics from 2010, TNBC comprises 12--20% of breast cancer cases and the percentage is rising ([@b7-or-43-06-1928]). Since TNBC is the most malignant breast cancer type and prone to metastasis and recurrence, common therapies usually fail to achieve satisfactory treatment effects ([@b8-or-43-06-1928]). Therefore, seeking novel therapeutic targets and agents for the treatment of TNBC is challenging and urgent. Usually, molecular targeted therapy aims at retrieving aberrant signaling transduction by selective inhibitors ([@b9-or-43-06-1928]). Considering the heterogeneity of TNBC, various categories of pathway inhibitors are used in clinical treatment ([@b10-or-43-06-1928]). However, a large proportion of patients with TNBC receiving monotherapy encounter drug-resistance, metastasis and recurrence ([@b11-or-43-06-1928]). Therefore, combined medications using inhibitors targeting different signaling pathways are emerging for the clinical treatment of TNBC ([@b12-or-43-06-1928]). Compared with traditional monotherapy, combined therapies usually are associated with enhanced efficacy and reduced risks of recurrence ([@b13-or-43-06-1928]--[@b15-or-43-06-1928]).

As a molecular chaperone, heat shock protein 90 (HSP90) aids various client proteins to fold into correct conformation ([@b16-or-43-06-1928]). However, the dysfunction of HSP90 leads to the misfolding and degradation of its client proteins. As a derivative of the antibiotic Geldanamycin, the HSP90 inhibitor 17-AAG (Tanespimycin) exhibits improved selectivity ([@b17-or-43-06-1928]). The binding affinity of 17-AAG to the HSP90 protein in tumor cells is \~100 times higher than to HSP90 protein in normal cells ([@b18-or-43-06-1928]). 17-AAG exhibits broad-spectrum antitumor activity against various types of cancer in pre-clinical studies ([@b19-or-43-06-1928]--[@b21-or-43-06-1928]). It is worth noting that HER2 is one of the client proteins of HSP90, and clinical trial results have revealed that HSP90 inhibitor 17-AAG treatment is beneficial in HER2-positive breast cancer ([@b22-or-43-06-1928]). A previous study has demonstrated that the combination of 17-AAG with Herceptin effectively overcomes the drug-resistance of Herceptin monotherapy ([@b23-or-43-06-1928]). As a previously identified biomarker for TNBC, the inhibitors of HSP90 may be beneficial to the combined medications of breast cancer ([@b24-or-43-06-1928],[@b25-or-43-06-1928]).

Dysfunction of histone acetylation is frequently observed in various types of cancer, including breast cancer ([@b26-or-43-06-1928]--[@b28-or-43-06-1928]). Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are responsible for the regulation of histone acetylation ([@b29-or-43-06-1928],[@b30-or-43-06-1928]). HAT and HDAC are important epigenetic targets for the development of antitumor agents ([@b31-or-43-06-1928]). Overwhelming evidence has demonstrated that HDAC inhibitors, including HDAC6 inhibitors, are promising for the combined treatment of TNBC ([@b32-or-43-06-1928]--[@b35-or-43-06-1928]). Besides the acetylation of histone H4, HDAC6 also regulates the acetylation of other proteins, including HSP90 and α-tubulin ([@b36-or-43-06-1928]). Additionally, a previous study has revealed that the overexpression of HDAC6 is closely associated with the metastasis and poor prognosis of patients with breast cancer ([@b37-or-43-06-1928]). As one of the client proteins of HSP90, HDAC6 regulates the acetylation of HSP90 reversely ([@b38-or-43-06-1928]). Acetylated HSP90 protein loses most of the chaperone activity, and the activity of its client proteins will abrogate afterwards ([@b39-or-43-06-1928]). As a HDAC inhibitor, Belinostat exhibits potent inhibitory effects on HDAC6 *in vitro*, with an IC~50~ value of 82 nM ([@b40-or-43-06-1928],[@b41-or-43-06-1928]). Previous studies have indicated that Belinostat is a beneficial choice for combined therapy of both blood and solid tumors ([@b42-or-43-06-1928],[@b43-or-43-06-1928]). Previous studies in other cancer types have indicated that the combination of HSP90 inhibitor and HDAC6 inhibitor exhibits more benefits than administration alone ([@b44-or-43-06-1928]--[@b46-or-43-06-1928]). Several HSP90 or HDAC combination therapies have been investigated in clinical trials ([@b12-or-43-06-1928],[@b47-or-43-06-1928]); however, most of them investigated combination therapies with chemotherapeutic drugs, such as cisplatin or paclitaxel. The primary clinical trial data indicated that TNBC may show response to HSP90 or HDAC combination therapy, but in combination with chemotherapeutic drugs unchangeable side effects caused by chemotherapeutic drugs remain. In TNBC, combination therapies with chemotherapeutic drugs exhibit high risk ([@b48-or-43-06-1928]) and occasionally have no benefit compared with single drug treatment ([@b49-or-43-06-1928],[@b50-or-43-06-1928]). Therefore, combined with chemotherapeutic drugs, HSP90 inhibitor or HDAC inhibitor may show the same high risk as single drug treatment in TNBC. Considering the internal mechanism of HDAC6 and HSP90, it was proposed that the HDAC6-HSP90 axis may show benefits in TNBC. If the HDAC6-HSP90 axis could show a combination effect, in further clinical trials, researchers may have the choice to avoid using chemotherapeutic drugs. The present study revealed that the HSP90 inhibitor 17-AAG synergizes with the HDAC6 inhibitor Belinostat in MDA-MB-231 cells, which may provide a beneficial reference for the clinical treatment of TNBC.

Materials and methods
=====================

### Cell lines and compounds

The ER-positive breast cancer MCF-7 cell line, TNBC MDA-MB-231 and BT549 cell lines, and a normal human mammary epithelial MCF-10A cell line were purchased from the American Type Culture Collection. All cell lines were cultured in a cell incubator (model no. thermo3111; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO~2~. The MDA-MB-231 and MCF-7 cells were cultured in DMEM (cat. no. L110KJ; BasalMedia, Inc.) supplemented with 10% fetal bovine serum (FBS; cat. no. 16000-044; Gibco; Thermo Fisher Scientific, Inc.) BT549 cells were cultured in DMEM supplemented with 10% FBS and 0.023 U/ml insulin. MCF-10A cells were cultured in DMEM/F12 (cat. no. L310KJ; BasalMedia, Inc.) supplemented with 5% donor horse serum (cat. no. 26050088; Gibco; Thermo Fisher Scientific, Inc.) and certain additives (20 ng/ml EGF, 10 µg/ml insulin and 10 ng/ml cholera toxin). Belinostat (HDAC6 inhibitor) and 17-AAG (HSP90 inhibitor) were purchased from Target molecule Corp. and prepared in DMSO as 50 mM stock solutions. The solutions were diluted in cell culture medium immediately prior to use.

### Cell viability assay and combination studies

Four different cell lines (MDA-MB-231, BT549, MCF-7 and MCF-10A) were seeded in 96-well flat bottom plates at a density of 3,000 cells/well and treated with 200 µM to 0.78 nM (double gradient dilution) 17-AAG or Belinostat at 37°C in triplicate 12 h later. The viability of cells was measured using the CellTiter-Glo Luminescent Cell Viability assay (Promega Corporation) at 72 h after treatment. The optical density of each well was recorded using a microplate reader (PerkinElmer Envision multimode plate reader; PerkinElmer, Inc.). A range of drug concentrations was added at their fixed ratio based on their respective individual IC~50~ values at 72 h ([@b51-or-43-06-1928]). Using the CompuSyn software ([@b52-or-43-06-1928]) (CompuSyn v1.0; ComboSyn, Inc.), combination indexes (CIs) were calculated according to the cell viability at corresponding concentrations. Briefly, the CI value indicates the interaction of co-administrated compounds: CI\<1 indicates synergism effect, CI=1 indicates additive effect and CI\>1 indicates antagonism effect ([@b53-or-43-06-1928]).

### Apoptosis and cell cycle analysis

For the apoptosis analysis, cells were seeded in 6-well flat bottom plates at a density of 1.5×10^5^ cells/well and treated with single 17-AAG (0.5 and 1.0 µM), single Belinostat (0.1 and 0.2 µM), or the combination of 17-AAG and Belinostat at 37°C for 12 h. After incubation for 72 h, cells were harvested in iced PBS buffer. Apoptosis was evaluated using the Annexin V-FITC Apoptosis Detection kit (Vazyme Biotech Co., Ltd.). Briefly, collected cells were re-suspended in 100 µl binding buffer and incubated with 5 µl propidium iodide (PI) and 5 µl Annexin V-FITC for 15 min in the dark at room temperature. Before analyzing apoptosis percentage using the FACSCalibur flow cytometry system (BD Biosciences), 400 µl binding buffer was added to the samples to stop the staining procedure. The apoptosis data were analyzed using FlowJo™ software (FlowJo 7.6.1; BD Biosciences), with ≥10,000 cells for each sample. For the cell cycle analysis by PI staining, cells were seeded and harvested as for the apoptosis assay. Each sample was fixed and re-suspended in 1 ml iced 70% ethanol at −20°C overnight. After washing twice with iced PBS buffer, samples were stained with PI in the dark at room temperature for 30 min. The PI stain was included in the Cell Cycle and Apoptosis Analysis kit (Yeasen). Subsequently, cell cycle analysis was performed using FACScan flow cytometry (FACS Canto II; BD Biosciences) by red fluorescence at an excitation wavelength of 488 nm, and the data were analyzed using ModFit software (ModFit LT v3.3; BD Biosciences).

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from MDA-MB-231 cells using the RNA Isolation kit (Beyotime Institute of Biotechnology). Each sample of 300 ng total RNA was reverse transcribed to cDNA using the HiScript II Q RT SuperMix for qPCR kit (Vazyme Biotech Co., Ltd.). The reverse transcription temperature protocol was as follows: 50°C for 15 min, followed by 80°C for 5 sec. The qPCR procedures were performed on the ViiA 7 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the ChamQ SYBR qPCR Master Mix (Low ROX Premixed) kit (Vazyme Biotech Co., Ltd.). The thermocycling program for the RT-qPCR reactions was as follow: Pre-denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 30 sec, followed by extension at 72°C for 1 min. Subsequently, the expression values of mRNA were calculated using the 2^−ΔΔCq^ method ([@b54-or-43-06-1928]), with GAPDH as a reference for normalization, and represented as fold change. Primers were synthesized by Sangon Biotech Co., Ltd. and are listed in [Table I](#tI-or-43-06-1928){ref-type="table"}.

### Western blotting

Cells were seeded in 6-well flat plates and split in 1X SDS sample loading buffer (250 mM Tris HCl pH 6.8, 10% SDS, 30% glycerol, 5% β-mercaptoethanol and 0.02% bromophenol blue). Protein concentrations were determined using the BCA Protein assay (Thermo Fisher Scientific, Inc.). Samples (25 µg/lane) were resolved by 6, 10 or 12% SDS-PAGE and transferred to 0.22-µm nitrocellulose membranes. Following blocking with 5% milk at room temperature for 1 h, the nitrocellulose membranes were washed four times for 15 min with TBS with 0.1% Tween-20 (TBST) buffer and incubated with primary antibodies (dilution, 1:1,000) at 4°C overnight. Subsequently, the membranes were washed four times with TBST buffer and incubated with horseradish peroxidase (HRP)-conjugated Goat Anti-Mouse lgG (cat. no. D110087; Sangon Biotech Co., Ltd.) and HRP-conjugated Goat Anti-Rabbit lgG (cat. no. D110058; Sangon Biotech Co., Ltd.) secondary antibodies (dilution, 1:10,000; BBI Life Sciences Corporation) for 1 h at room temperature. The bands were visualized using an enhanced chemiluminescence kit (Thermo Fisher Scientific, Inc.) with a ChemiScope 3400 mini imaging system (Clinx Science Instrument Co., Ltd.). Densitometry was performed for each group using ImageJ 1.50b software (National Institutes of Health). All primary antibodies used are listed in [Table II](#tII-or-43-06-1928){ref-type="table"}.

### RNA-sequencing (RNA-seq) data collection and analysis

To characterize the genomic impact of single and combined compound treatment, RNA-seq data was collected using 1.5×10^5^ MDA-MB-231 cells treated with DMSO as a control, 17-AAG (1.0 µM), Belinostat (0.2 µM) and the combination of 17-AAG and Belinostat at 37°C for 72 h. After 24 h, total RNA was isolated and purified using DNaseI (Takara Bio, Inc.) and Dynabeads Oligo (dT) 25 (Thermo Fisher Scientific, Inc.). Subsequently, purified RNA (100 ng) was used for cDNA library construction, using the NEBNext Ultra™ RNA Library Prep kit for Illumina (cat. no. E7530L; New England BioLabs, Inc.). Sequencing data was collected on an Illumina HiSeq 2500 instrument. Subsequently, paired-end reads were processed using the Tophat2 v2.1.1 software package ([@b55-or-43-06-1928]), with the GRCh38/hg18 Ensembl transcript set as a reference. Following transcript assembly using the Cufflinks v2.2.1 software package ([@b56-or-43-06-1928]), differentially expressed genes (\|log~2~fold-change\| \>0.5 and P\<0.05) were identified using Cuffdiff 2 ([@b57-or-43-06-1928]). From the list of differentially expressed genes, each gene was checked in the Gene database of the National Center for Biotechnology Information (<https://www.ncbi.nlm.nih.gov/gene/>). According to the relevant abstract description of genes in NCBI, only the most migration-related or metastasis-related genes were selected for the final heatmap. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<http://www.kegg.jp/>) was used for pathway analysis. Using the GeneAnswers v3.0 package ([@b58-or-43-06-1928]) of the Bioconductor project, the P-values of involved KEGG pathways were calculated with a threshold value of 0.1, based on all differentially expressed genes. Finally, the heatmap and pathways histogram were plotted using the ggplot2 v2.1.0 package in R (<http://www.rdocumentation.org/packages/gglot2/versions/2.1.0>). The raw sequencing data and processed expression tables have been deposited to the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>; accession no. GSE129944).

### Detection of reactive oxygen species (ROS)

MDA-MB-231 cells were seeded in 6-well plates at a density of 7.5×10^4^ cells/ml and permitted to adhere overnight. After cells were treated with 0.2 µM Belinostat, 1 µM 17-AAG or the combination at 37°C for 3 days, cells were stained with 1 µM DCFH-DA for 30 min in the dark at 37°C. Subsequently, cells were washed three times with PBS and subjected to FACScan flow cytometry (FACS Canto II; BD Biosciences). Green fluorescence FITC (FL1) was detected at 488 nm (excitation wavelength) and 530 nm (emission wavelength). FlowJo™ software (FlowJo 7.6.1; BD Biosciences) was used to calculate and analyze the data. Fluorescence microscopy (magnification, ×40) was used to capture images with fixed exposure time.

### Wound healing assay

For the wound healing assay, coordinates were marked on the 35-mm dish, and MDA-MB-231 cells were inoculated at a density of 1.5×10^6^ cells/well. When the confluence was \~100%, cells were rinsed twice with PBS, and serum-free DMEM was added for cell starvation. After cells were starved for 24 h, three marks were scratched on the dish covered with cells with a 200-µl pipette tip. Subsequently, the dish was washed twice with PBS to remove cell debris, and serum-free DMEM containing 0.2 µM Belinostat, 1 µM 17-AAG or the combination of both was added after scratching. Images were captured under an inverted light microscope (magnification, ×40) at different time points. The cell scratch area at each coordinate point was recorded. The relative migration area was calculated, and average values were taken for comparison. The area of cells was calculated for each group using ImageJ 1.50b software (National Institutes of Health) The wound-closing procedure was observed for 36 h, and images were captured at 0 and 36 h, respectively.

### Cell migration and invasion assays

For the cell migration assay, serum-free medium was added to the Transwell (cat. no. 353097; Corning Inc.) and outer chamber, and the membrane of the chamber was hydrated 1 h later. A total of 1.5×10^5^ MDA-MB-231 cells were plated into 35-mm dishes containing serum-free DMEM. Following starvation at 37°C for 12--24 h to further remove the effect of serum, cells were digested, centrifuged at 300 × g at room temperature for 5 min and the media were discarded. Subsequently, cells were washed once or twice with PBS, and re-suspended with the serum-free culture medium containing 0.1% BSA (Sigma-Aldrich; Merck KGaA) The density of cells was adjusted to 1×10^6^ cells/ml. A total of 1.0×10^5^ MDA-MB-231 cells were added to the upper Transwell chamber containing 0.2 µM Belinostat, 1 µM 17-AAG or combination of both, and 600 µl DMEM containing 10% FBS was added to the lower chamber of the 24-well plate. Placed on a 24-well plate, the surface of the Transwell compartment membrane was carefully observed for bubble formation. Following incubation at 37°C for 24 h, Transwell cells were washed twice with PBS, and a cotton swab was used to remove cells from the upper chamber. Subsequently, cells were fixed with 90% ethanol at room temperature for 15 min, and the membrane was dried and stained with 0.1% crystal violet at room temperature for 30 min. Finally, the Transwell membrane was cut off and placed on a glass slide for microscopic observation, and six locations were randomly selected for imaging by means of an inverted light microscope (magnification, ×40). The number of cells was calculated for each group using ImageJ 1.50b software (National Institutes of Health). For the cell invasion assay, the procedure was similar to the cell migration assay, except that the Transwell membranes were pre-coated with 50 mg/ml Matrigel (BD Biosciences) at 37°C for 1 h.

### Small interfering RNA (siRNA) transfection

TEA domain family members (TEADs) siRNAs were synthesized by Shanghai GenePharma Co., Ltd. Cells were seeded in a 6-well plate to be 60--80% confluent. A total of 1.5 µl siRNA (20 µM) and 9 µl Lipofectamine^®^ RNAiMAX reagent (cat. no. 13778150; Invitrogen; Thermo Fisher Scientific, Inc.) were mixed with 150 µl Opti MEM medium (cat. no. 31985070; Gibco; Thermo Fisher Scientific, Inc.). The final concentration of siRNAs was 25 pM. Next, diluted siRNA was added to diluted Lipofectamine RNAiMAX reagent and cultured 5 min at room temperature. siRNA-lipid complex was added to cells for 6--8 h at 37°C and cells were re-cultured in complete medium for 48 h at 37°C. Subsequent experiments were performed after the cells were transfected for 48 h. Control siRNA was used as a negative control. siRNAs used for siRNA transfection are listed in [Table III](#tIII-or-43-06-1928){ref-type="table"}.

### Statistical analysis

All data are presented as the mean ± SEM. All experiments, including western blotting, were performed in duplicate or triplicate. Western blotting semi-quantification was implemented by ImageJ 1.50b (National Institutes of Health) Statistical analyses were carried out using the GraphPad 5.0 software (GraphPad Software, Inc.). Comparisons between two groups were implemented using the unpaired two-tailed Student\'s t-test. Comparisons of three groups were executed by multiple t-tests with the Holm-Sidak method, as recommended by the GraphPad software. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### TNBC cell lines maintain relatively high expression levels of HSP90 and HDAC6

To confirm whether TNBC cell lines have relatively high expression levels of both HSP90 and HDAC6, the mRNA expression and protein abundance levels of HSP90 and HDAC6 were detected in four breast cell lines. It was identified that the mRNA expression levels of HDAC6 were upregulated in TNBC cell lines, but for HSP90, the two subunits, HSP90AA1 and HSP90AB1, exhibited no significant differences across the four cell lines examined ([Fig. 1A and B](#f1-or-43-06-1928){ref-type="fig"}). Based on the protein expression levels presented in [Fig. 1C](#f1-or-43-06-1928){ref-type="fig"}, HSP90 exhibited similar abundance in the cell lines, except in BT549 where its expression was slightly decreased. Statistical analysis demonstrated that HSP90 protein levels did not no differ across the four cell lines ([Fig. 1D](#f1-or-43-06-1928){ref-type="fig"}). However, HDAC6 expression was upregulated in TNBC cells which was consistent with the results for mRNA expression. Overall, the results indicated that TNBC cell lines maintain relatively high expression levels of HDAC6, whereas the expression levels of HSP90 were almost consistent. It may be speculated that the combination of HSP90 inhibitor and HDAC6 inhibitor could have an improved therapeutic effect in TNBC cell lines. As aforementioned, reciprocal effects exist between HSP90 and HDAC6 ([@b38-or-43-06-1928]). The present study aimed to determine whether combined treatment with HSP90 inhibitor and HDAC6 inhibitor may achieve enhanced efficacy compared with treatment with either inhibitor alone.

### Synergistic effects exist between HSP90 inhibitor 17-AAG and HDAC6 inhibitor Belinostat in MDA-MB-231 cells

To determine whether synergistic effects exist between the HSP90 inhibitor 17-AAG and HDAC6 inhibitor Belinostat, the IC~50~ value and cell viability of these two drugs were measured to generate a concentration-inhibition matrix for combined treatment ([Fig. 2A and B](#f2-or-43-06-1928){ref-type="fig"}). Based on a previous study ([@b51-or-43-06-1928]), the effects of the combination were calculated using the CI, because it has been recognized that the fixed dose ratio of two drugs based on individual IC~50~ values can achieve a rational CI. MDA-MB-231, MCF-10A, MCF-7 and BT549 cells were treated with three different concentrations of 17-AAG and Belinostat. The effective concentration ratio between 17-AAG and Belinostat was \~5, 0.023, 1.8 and 0.0008, respectively ([Fig. 2A and B](#f2-or-43-06-1928){ref-type="fig"}). In MCF-10A and BT549 cells, the CI values were \>1 at three groups of concentrations selected according to effective concentration ratio between 17-AAG and Belinostat ([Fig. 2C](#f2-or-43-06-1928){ref-type="fig"}). This indicated that the two drugs have an antagonistic effect. The antagonistic effect may be caused by high sensitivity to 17-AAG of MCF-10A and BT549 cells. BT549 cells exhibited higher sensitivity to 17-AAG than Belinostat ([Fig. 2A and B](#f2-or-43-06-1928){ref-type="fig"}), which could not be observed and concluded from [Fig. 1](#f1-or-43-06-1928){ref-type="fig"}. The mechanism of the dominant effect of 17-AAG in BT549 cells requires further study; however, the present study aimed to explore the combination effect of the HSP90-HDAC6 axis. The CI values were \<1 at different concentrations in MDA-MB-231 and MCF7 cells. However, considering the IC~50~ value of 17-AAG in MCF-7, it was revealed that the difference in cell inhibition rate was not obvious at the near drug concentration ([Fig. 2C](#f2-or-43-06-1928){ref-type="fig"}). Therefore, when setting the fixed molar ratio of the two drugs, the selected three concentration points would lead to a Fa value higher than that of MDA-MB-231. These results indicated that 17-AAG and Belinostat exhibited the best synergistic effect in MDA-MB-231 cells compared with in the other three breast cell lines. Three concentration groups in MDA-MB-231 cells were established for 17-AAG and Belinostat, including 0.50 µM 17-AAG and 0.10 µM Belinostat, 0.80 µM 17-AAG and 0.16 µM Belinostat, and 1.00 µM 17-AAG and 0.20 µM Belinostat ([Fig. 2D](#f2-or-43-06-1928){ref-type="fig"}).

### Combination of 17-AAG and Belinostat leads to enhanced cell cycle arrest and apoptosis in MDA-MB-231 cells

In addition to combination index, the combination of 17-AAG and Belinostat also led to enhanced cell cycle arrest and apoptosis in MDA-MB-231 cells. Two combination groups with low CI values (0.1 µM Belinostat with 0.5 µM 17-AAG, and 0.2 µM Belinostat with 1.0 µM 17-AAG) were selected to treat MDA-MB-231 cells for 3 days. The relative apoptosis rate was not significantly increased in cells treated with 17-AAG or Belinostat ([Fig. 3A and C](#f3-or-43-06-1928){ref-type="fig"}). The combination of 17-AAG and Belinostat led to a marked increase in apoptosis, and the total apoptosis rate increased with the elevation of concentrations ([Fig. 3A and C](#f3-or-43-06-1928){ref-type="fig"}). Additionally, a higher proportion of cells were arrested in the G~2~ phase following the combined treatment with 17-AAG and Belinostat compared with the single treatment of 17-AAG or Belinostat alone ([Fig. 3B](#f3-or-43-06-1928){ref-type="fig"}), and the rate of G~2~ phase arrest in the combined treatment group was higher than that in the single treatment groups ([Fig. 3D](#f3-or-43-06-1928){ref-type="fig"}). Consistent with the flow cytometry results, western blotting results demonstrated that the levels of cleaved poly (ADP-ribose) polymerase and caspase 3 were upregulated in the combination group. In addition, the protein abundance of CDK1 phosphorylation (p-CDK1) was upregulated in the combination group and in the single 17-AAG (1 µM) group, indicating increased inactivation of CDK1. Furthermore, the protein abundance of cyclin B1 was downregulated in the combination group, indicating an increased proportion of G~2~/M phase arrest.

### Reciprocal interactions between Belinostat and HSP90, and 17-AAG and HDAC6

According to a previous study ([@b59-or-43-06-1928]), reciprocal interactions may exist between HSP90 and HDAC6. To determine whether Belinostat affected HSP90 expression, and whether 17-AAG affected the protein abundance of HDAC6, qPCR and western blotting were performed. Subsequently, it was demonstrated that Belinostat downregulated the transcription levels of HSP90 (HSP90AA1 and HSP90AB1; [Fig. 4A](#f4-or-43-06-1928){ref-type="fig"}). However, Belinostat did not reduce the HSP90 protein level ([Fig. 4B](#f4-or-43-06-1928){ref-type="fig"}). Compared with the treatment with Belinostat alone, the acetylation of HSP90 was sharply enhanced in the combination group, indicating that 17-AAG amplified the acetylation effect of Belinostat on HSP90. Although Belinostat induced higher acetylation of α-tubulin than 17-AAG, this effect was not further enhanced in the combination group. Similarly, the protein abundance of HDAC6 was decreased following treatment with 17-AAG alone, whereas this effect was not further enhanced in the combination group ([Fig. 4B](#f4-or-43-06-1928){ref-type="fig"}).

### RNA-seq analysis suggests that the combination of 17-AAG and Belinostat may achieve enhanced inhibition of the migration and invasion of MDA-MB-231 cells

To determine the specific genes and pathways that are responsible for the synergistic effect of the combination of 17-AAG and Belinostat, RNA-seq was carried out using MDA-MB-231 cells treated with 17-AAG alone, Belinostat alone, and the combination of 17-AAG and Belinostat. The IC~50~ ratio of Belinostat and 17-AAG was \~1 vs. 5, as shown in [Fig. 2A and B](#f2-or-43-06-1928){ref-type="fig"}, and the concentration used for RNA-seq was selected according to the previously calculated CI value, apoptosis and cell cycle experiments. When the dose for 17-AAG was 1.0 µM and that for Belinostat was 0.2 µM, cell viability and apoptosis data exhibited an improved combination effect. Overall, this dosage was selected for RNA-Seq exploration. The results demonstrated that the numbers of differentially expressed genes were 3,576, 1,517 and 874, for the treatment of 17-AAG alone compared with the DMSO group, Belinostat alone compared with the DMSO group, and the combination group compared with the DMSO group, respectively. The numbers of shared and unique differentially expressed genes for each treatment group were presented as a Venn diagram ([Fig. 5A](#f5-or-43-06-1928){ref-type="fig"}). In terms of pathways analysis, the P-values for each significantly enriched KEGG pathway were plotted as a histogram for each treatment group, and the length of each bar is proportional to the P-value of each KEGG pathway. the 'cell cycle' pathway was more significantly enriched than the 'TGF-beta signaling pathway' and the 'Focal adhesion' pathway, for both the treatment of 17-AAG alone, or Belinostat alone ([Fig. 5B and C](#f5-or-43-06-1928){ref-type="fig"}). However, 'Focal adhesion', 'TGF-beta signaling pathway' and 'Regulation of actin cytoskeleton' were the most significantly enriched KEGG pathways in the combination group ([Fig. 5D](#f5-or-43-06-1928){ref-type="fig"}). For treatment with 17-AAG alone, the P-values for 'Focal adhesion', 'TGF-beta signaling pathway' and 'Regulation of actin cytoskeleton' were 1.9×10^−3^, 2.1×10^−3^ and 2.9×10^−3^, respectively. For treatment with Belinostat alone, the P-values for 'Focal adhesion' and 'TGF-beta signaling pathway' were 0.014 and 0.022, respectively. However, in the combination group, the P-values for 'Focal Adhesion', 'TGF-beta signaling pathway' and 'Regulation of actin cytoskeleton' were 6.8×10^−5^, 2.9×10^−4^ and 4.7×10^−4^, respectively. In addition, considering the over-representation of the 'Oxidative phosphorylation' pathway in MDA-MB-231 cells following with treatment with Belinostat alone, the accumulation ROS in different groups was examined. It was identified that the ROS level was significantly higher in the combination group ([Fig. S1A](#SD1-or-43-06-1928){ref-type="supplementary-material"}). In addition, several genes that regulate relevant signaling pathways were also significantly affected in the combination group, including EGFR, COX5B and UBA52 ([Fig. S1B](#SD1-or-43-06-1928){ref-type="supplementary-material"}). Consistent with the pathway analysis, dozens of migration-associated genes were identified in the list of differentially expressed genes. Some of them were observed in the shared list of all the treatment groups, including the treatment with 17-AAG alone, Belinostat alone and the combination group ([Fig. 5E](#f5-or-43-06-1928){ref-type="fig"}), whereas some of them were observed only in the list of the combination group ([Fig. 5F](#f5-or-43-06-1928){ref-type="fig"}). As these pathways and genes mainly mediate the migration and invasion of cancer cells, these findings indicated that the combination of 17-AAG and Belinostat may have enhanced the inhibition of the migration and invasion of MDA-MB-231 cells compared with treatment with 17-AAG or Belinostat alone.

### Combination of 17-AAG and Belinostat leads to enhanced inhibition of the migration and invasion of MDA-MB-231 cells

To confirm whether the combination of 17-AAG and Belinostat may have inhibitory effects on migration and invasion, MDA-MB-231 cells were treated with single or combined compounds and subjected to Transwell and wound-healing assays. The doses for 17-AAG and for Belinostat were consistent with those for RNA-seq. Compared with the treatment of 17-AAG alone, or Belinostat alone, the numbers of migrating and invasive cells were decreased following the combined treatment with 17-AAG and Belinostat for 24 h ([Fig. 6A and B](#f6-or-43-06-1928){ref-type="fig"}). Similarly, in the wounding healing assay, it was identified that the migration of cells was significantly suppressed following the combined treatment with 17-AAG and Belinostat for 24 h ([Fig. 6C](#f6-or-43-06-1928){ref-type="fig"}). According to the RNA-seq data analysis, relevant signaling pathways and genes mediating cell migration and invasion were investigated ([@b60-or-43-06-1928],[@b61-or-43-06-1928]). TEAD1 is one of the differentially expressed genes shared by the single and combined treatment groups ([Fig. 5E](#f5-or-43-06-1928){ref-type="fig"}). Additionally, significant downregulation was observed for the TEAD family proteins in the combination group ([Fig. 6D](#f6-or-43-06-1928){ref-type="fig"}). Consistent with RNA sequencing results ([Fig. 5E](#f5-or-43-06-1928){ref-type="fig"}), western blotting results demonstrated that the abundance of TEAD family proteins was decreased in the combination group ([Fig. 6E](#f6-or-43-06-1928){ref-type="fig"}). Additionally, the phosphorylation of YAP and MLC was increased in the combination group. Subsequently, siRNA was used to knockdown TEAD genes in MDA-MB-231 cells. The knockdown efficiency of each siRNA was \>80% compared with the normal group ([Fig. S2A](#SD1-or-43-06-1928){ref-type="supplementary-material"}). Additionally, the protein expression levels of TEADs were decreased ([Fig. S2B](#SD1-or-43-06-1928){ref-type="supplementary-material"}). As shown in the results of the cell migration assay ([Fig. 6F](#f6-or-43-06-1928){ref-type="fig"}), TEAD1 exhibited a greater effect on migration of MDA-MB-231 cells than other TEADs, whereas TEAD3 had no effect on cell migration.

Discussion
==========

The present study reported the synergistic effect of the HSP90 inhibitor 17-AAG and the HDAC6 inhibitor Belinostat on the proliferation, as well as migration and invasion, of TNBC MDA-MB-231 cells. HSP90 has been reported as a biomarker of TNBC ([@b24-or-43-06-1928],[@b25-or-43-06-1928]), and HDACs are considered to be a therapeutic target of TNBC ([@b62-or-43-06-1928]). According to previous studies, HSP90 regulates the protein folding of HDAC6, whereas HDAC6 reversely promotes the acetylation of HSP90 ([@b38-or-43-06-1928],[@b39-or-43-06-1928]). Higher expression levels of HSP90 and HDAC6 were observed in TNBC BT549 and MDA-MB-231 cell lines compared with in the non-TNBC MCF-7 cell line and normal breast MCF-10A cell line, suggesting that the combined treatment of HSP90 inhibitor and HDAC6 inhibitor may achieve synergistic efficacy ([@b63-or-43-06-1928]). Subsequently, it was revealed that the combined treatment with HSP90 inhibitor 17-AAG and HDAC6 inhibitor Belinostat synergistically inhibited the proliferation of MDA-MB-231 cells, with a CI\<1 in three different concentration groups ([Fig. 1D](#f1-or-43-06-1928){ref-type="fig"}). Additionally, the inhibition rate in the combination group was greater than the sum of inhibition rates of the two single-treatment groups, which is a remarkable feature of this combination formula.

According to previous studies of the interactions between HSP90 and HDAC6, the inhibitors of these two targets may crosstalk ([@b38-or-43-06-1928],[@b64-or-43-06-1928],[@b65-or-43-06-1928]). The results revealed that the HDAC6 inhibitor Belinostat downregulated the mRNA expression of HSP90, whereas the HSP90 inhibitor 17-AAG significantly downregulated the protein abundance of HDAC6. Indeed, HDAC inhibitors have been identified to turn on gene expression via an increase in histone acetylation and chromatin opening ([@b66-or-43-06-1928]). However, subsequent studies have revealed that open chromatin resulting from inhibition of histone deacetylases can result in either the upregulation or the repression of genes ([@b67-or-43-06-1928],[@b68-or-43-06-1928]). Due to this reciprocal interaction, the acetylation rate of HSP90 and α-tubulin were significantly elevated in the combination group of 17-AAG and Belinostat. The difference between mRNA and protein expression may be caused by time delay between transcription and translation. The decrease in mRNA may require more time to impact the protein level. In order to investigate the involved genes and pathways which are responsible for the synergistic effect of the combination of 17-AAG and Belinostat, RNA-seq data was collected and analyzed. It was identified that migration and invasion-associated pathways were the most significantly enriched in the combination group. Subsequent results confirmed the significant downregulation of TEAD family proteins, and increased phosphorylation of YAP and MLC, indicating the suppression of the Hippo signaling pathway and Rho-mediated cell migration ([Fig. 7](#f7-or-43-06-1928){ref-type="fig"}). The present study revealed that the protein expression levels of YAP were decreased in the combination group, and previous studies have demonstrated that YAP is associated with the occurrence of breast cancer ([@b69-or-43-06-1928]--[@b71-or-43-06-1928]). YAP can enhance cell growth and tumor growth ([@b72-or-43-06-1928],[@b73-or-43-06-1928]). Therefore, the downregulation of YAP may explain why the combination group can inhibit cell proliferation better than a single drug. Overall, the combination of 17-AAG and Belinostat increased the phosphorylation of YAP and modulator of VRAC current 1 (MLC), and decreased the expression of YAP and TEAD family proteins, leading to the suppression of Hippo signaling pathway ([@b74-or-43-06-1928]) and Rho-mediated cell migration ([@b75-or-43-06-1928],[@b76-or-43-06-1928]). These alterations may contribute to the enhanced inhibition of the combination group, in terms of migration and invasion of MDA-MB-231 cells. TEAD is a well investigated regulator that mediates the migration and invasion of cancer cells. Previous studies have indicated the key regulatory role of the YY1 associated protein 1(YAP)/TAZ/TEAD complex in the metastasis of breast cancer ([@b77-or-43-06-1928],[@b78-or-43-06-1928]). Transcriptional co-activator with PDZ-binding motif (TAZ) is structurally similar transcriptional co-factors involved in multiple cellular processes including proliferation, organ growth and stem cell differentiation with YAP ([@b79-or-43-06-1928]). In addition, as a transcription factor, the alteration in TEAD expression may have a wider and deeper impact on the migration and invasion of cancer cells compared with various other genes. Previous studies have indicated the effect of HSP90 and HDAC6 ([@b80-or-43-06-1928],[@b81-or-43-06-1928]) in regulating the function of the YAP/TAZ/TEAD complex. However, the detailed mechanism of how the TEAD genes affected MDA-MB-231 cell migration requires further research. The observation in MDA-MB-231 cells require verification in BT549 or other TNBC cell lines in addition to *in vivo* studies to verify this effect. Overall, according to previous experiment on MDA-MB-231 cells, the combination of 17-AAG and Belinostat has great potential for the treatment of TNBC. However, the enhanced efficacy of this combination requires clinical data to substantiate, before it actually benefits the patients with TNBC.

In conclusion, as a heterogeneous subtype of breast cancer, TNBC is challenging for clinical treatment due to the high risk of metastasis and recurrence. The current study reported the enhanced inhibitory effect of the combination of 17-AAG and Belinostat on the proliferation, cell cycle progression and survival of TNBC MDA-MB-231 cells. Additionally, the inhibition rate in the combination group was greater than the sum of the inhibition rates in the single-treatment groups. According to the RNA-seq data analysis, this combination may exhibit enhanced inhibitory effects on the migration and invasion of MDA-MB-231 cells, which was subsequently confirmed by migration and invasion assays. In addition, it was revealed that this enhanced efficacy may be achieved through the suppression of the Hippo signaling pathway and Rho-mediated cell migration ([@b78-or-43-06-1928]). Since the anti-metastasis feature of this combination has great potential for the treatment of TNBC, it was concluded that the effect and mechanism of this combination provided a novel strategy, as well as beneficial reference, for the clinical treatment of TNBC, based on experiments in MDA-MB-231 cells.
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![Relatively high expression of HSP90 and HDAC6 in TNBC cells. (A) mRNA expression levels of HSP90 subunits (HSP90AA1 and HSP90AB1) exhibited no differences across the four cell lines. (B) mRNA expression levels of HDAC6 were higher in TNBC cell lines. (C) Protein abundance of HDAC6 and HSP90 in the four cell lines. (D) Protein semi-quantification of HDAC6 and HSP90 in breast cancer cell lines and the normal breast MCF-10 cell line. Data are presented as the mean ± SEM. \*P\<0.05, \*\*P\<0.01 vs. BT549; ^\#^P\<0.05, ^\#\#\#\#^P\<0.0001 vs. MDA-MB-231. TNBC, triple-negative breast cancer; HDAC6, histone deacetylase 6; HSP90, heat shock protein 90; ns, not significant.](OR-43-06-1928-g00){#f1-or-43-06-1928}

![Synergistic effect exists between 17-AAG and Belinostat in breast cancer cell lines. (A) IC~50~ value for Belinostat against the viability of breast cancer cell lines following compound treatment for 72 h. (B) IC~50~ value for 17-AAG against the viability of breast cancer cell lines following compound treatment for 72 h. (C) Synergistic effect between 17-AAG and Belinostat presented as the Fa-CI curve plotted by the CompuSyn software. Squares represent combined groups of different concentrations. CI\<1 indicated that synergistic effect was observed for the combination of 17-AAG and Belinostat. (D) Significant enhancement of growth inhibition was observed for the three concentration groups following combined treatment with 17-AAG and Belinostat for 72 h. Data are presented as the mean ± SEM. \*\*\*P\<0.001 vs. Belinostat; ^\#\#\#^P\<0.001 vs. 17-AAG. CI, combination index; Fa, cell inhibition.](OR-43-06-1928-g01){#f2-or-43-06-1928}

###### 

Combination of 17-AAG and Belinostat induces enhanced cell cycle arrest and apoptosis. (A) Increased apoptosis was observed in MDA-MB-231 cells, for the two combination groups of 17-AAG and Belinostat, compared with treatment with 17-AAG or Belinostat alone. Combination of 17-AAG and Belinostat induces enhanced cell cycle arrest and apoptosis. (B) Increased G~2~/M cell cycle arrest was observed in MDA-MB-231 cells for the two combination groups of 17-AAG and Belinostat, compared with treatment with 17-AAG or Belinostat alone. (C) Quantified rate of apoptosis for each sample following compound treatment for 72 h. (D) Quantified rate of G~2~/M cell cycle arrest for each sample, following compound treatment for 72 h. (E) Western blotting results were consistent with the elevated apoptosis and cell cycle arrest revealed by flow cytometry. Data are presented as the mean ± SEM. \*\*P\<0.01, \*\*\*P\<0.001. p-, phosphorylated-.
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![Reciprocal interactions between HSP90i 17-AAG and HDAC6i Belinostat. (A) HDAC6i Belinostat decreased the mRNA expression levels of HSP90 subunits (HSP90AA1 and HSP90AB1) in a concentration-dependent manner. MDA-MB-231 cells were treated with 0.1 µM or 0.2 µM Belinostat for 72 h. (B) HSP90i 17-AAG significantly enhanced the acetylation effect of Belinostat on HSP90, as shown for Ac-k, whereas 17-AAG alone showed stronger inhibition of HDAC6 expression than Belinostat alone. 17-AAG alone increased the acetylation level of α-tubulin, while this effect was enhanced in the combination group. HSP90 and α-tubulin were used as internal references, and compound treatment duration was 72 h. Data are shown as the mean ± SEM. \*\*\*P\<0.001. HSP90i, HSP90 inhibitor; HDAC6i, HDAC6 inhibitor; HDAC6, histone deacetylase 6; HSP90, heat shock protein 90; Ac, acetylated; Ac-k, Acetylated-lysine antibody.](OR-43-06-1928-g04){#f4-or-43-06-1928}

###### 

Pathway statistics and heatmap analysis for RNA-sequencing data of different treatment groups. (A) Venn diagram for shared and unique numbers of differentially expressed genes in the treatment groups of 17-AAG alone, Belinostat alone, and the combination of 17-AAG and Belinostat. The total number of shared differentially expressed genes for the three treatment groups was 360, whereas the total number of unique differentially expressed genes for the combination group was 185. (B) Most enriched KEGG pathways of MDA-MB-231 cells, following the treatment with 17-AAG alone. The 'Cell cycle' and 'Oxidative phosphorylation' pathways were more significantly enriched than three migration-related pathways, including 'Focal adhesion', 'TGF-beta signaling pathway' and 'Regulation of actin cytoskeleton'. (C) Most enriched KEGG pathways of MDA-MB-231 cells following treatment with Belinostat alone. The 'Cell cycle' and 'Oxidative phosphorylation' pathways were more significantly enriched than three migration-related pathways, including 'Focal adhesion' and 'TGF-beta signaling pathway'. (D) Most enriched KEGG pathways of MDA-MB-231 cells following combined treatment with 17-AAG and Belinostat. Unlike for the treatment groups of 17-AAG or Belinostat alone, the 'Focal adhesion', 'TGF-beta signaling pathway' and 'Regulation of actin cytoskeleton' were more enriched than the 'Cell cycle' pathway, and other typical signaling pathways, including P53 signaling pathway, MAPK signaling pathway and Wnt signaling pathway. Pathway statistics and heatmap analysis for RNA-sequencing data of different treatment groups. ((E) Heatmap of selected differentially expressed genes from the shared list (n=360) of the three treatment groups, including 17-AAG alone, Belinostat alone and the combination group. These genes are associated with the migration or cytoskeleton remodeling of cells, according to previous studies ([@b82-or-43-06-1928]--[@b84-or-43-06-1928]). The relative expression values were compared with the DMSO group, and relatively higher expression is presented in red, whereas relatively lower expression is presented in blue. Pathway statistics and heatmap analysis for RNA-sequencing data of different treatment groups. (F) Heatmap of selected differentially expressed genes from the unique list (n=185) for the combination group, instead of the treatment groups of 17-AAG or Belinostat alone. These genes were associated with the migration or survival of tumor cells, according to previous studies ([@b85-or-43-06-1928]--[@b87-or-43-06-1928]). The relative expression values were compared with the DMSO group, and relatively higher expression was presented in red, whereas relatively lower expression was presented in blue. KEGG, Kyoto Encyclopedia of Genes and Genomes.
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###### 

Enhanced inhibition of the migration and invasion of MDA-MB-231 cells. (A) Transwell migration assays demonstrated that enhanced inhibition was observed for the combination group of 17-AAG and Belinostat in MDA-MB-231 cells. Magnification, ×40. (B) Transwell invasion assay demonstrated that enhanced inhibition was observed for the combination group of 17-AAG and Belinostat in MDA-MB-231 cells. Magnification, ×40. (C) Wound healing assays revealed that enhanced inhibition was observed for the combination group of 17-AAG and Belinostat in MDA-MB-231 cells. Magnification, ×40. Enhanced inhibition of the migration and invasion of MDA-MB-231 cells. (D) Significant downregulation of expression was observed for the TEAD family proteins in the combination group compared with in the treatment groups of 17-AAG or Belinostat alone. (E) Phosphorylation of YAP and MLC was significantly increased in the combination group, indicating the suppression of migration and invasion-associated pathways. Decreased protein abundance of the TEAD family was consistent with the mRNA downregulation. (F) Transwell migration assays demonstrated that the knockdown of TEADs genes inhibited the migration of MDA-MB-231 cells. Magnification, ×40. Data are presented as the mean ± SEM. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001. p-, phosphorylated; TEAD, TEA domain family member; ns, not significant; YAP, YY1 associated protein 1; TAZ, tafazzin; MLC, modulator of VRAC current 1; si, small interfering RNA; NC, negative control.
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![Proposed mechanism for the combination of 17-AAG and Belinostat exhibiting inhibitory effects on proliferation and invasion. HDAC6, histone deacetylase 6; HSP90, heat shock protein 90; TEAD, TEA domain family member; MLC, modulator of VRAC current 1; YAP, YY1 associated protein 1.](OR-43-06-1928-g10){#f7-or-43-06-1928}

###### 

List of primers used for quantitative PCR.

  Primer             Sequence (5′-3′)
  ------------------ -------------------------
  HSP90AA1-Forward   GCTTGACCAATGACTGGGAAG
  HSP90AA1-Reverse   AGCTCCTCACAGTTATCCATGA
  HSP90AB1-Forward   CATCTCCATGATTGGGCAGTT
  HSP90AB1-Reverse   CTTTGACCCGCCTCTCTTCTA
  GAPDH-Forward      AGGTCGGTGTGAACGGATTTG
  GAPDH-Reverse      GGGGTCGTTGATGGCAACA
  TEAD1-Forward      ATGCCAACCATTCTTACAGTGAC
  TEAD1-Reverse      ACAGTTCCTTTAAGCCACCTTTC
  TEAD2-Forward      CTTCGTGGAACCGCCAGAT
  TEAD2-Reverse      GGAGGCCACCCTTTTTCTCA
  TEAD3-Forward      GCTCCTGGAGTATTCAGCCTT
  TEAD3-Reverse      GTCGGCCCAGAACTTGACAA
  TEAD4-Forward      GGACACTACTCTTACCGCATCC
  TEAD4-Reverse      TCAAAGACATAGGCAATGCACA
  YAP-Forward        CGCTCTTCAACGCCGTCA
  YAP-Reverse        AGTACTGGCCTGTCGGGAGT
  TAZ-Forward        CACCGTGTCCAATCACCAGTC
  TAZ-Reverse        TCCAACGCATCAACTTCAGGT
  EGFR-Forward       AGGCACGAGTAACAAGCTCAC
  EGFR-Reverse       ATGAGGACATAACCAGCCACC
  COX5B-Forward      ATCTGGAGGTGGTGTTCCCA
  COX5B-Reverse      TCCAGTCCCTTCTTTGCAGC
  COX7C-Forward      GGGCCCTGGGAAGAATTTGC
  COX7C-Reverse      GGAAGGGTGTAGCAAATGCAGA
  UBA52-Forward      GTCGTGCGGACGCAAACAT
  UBA52-Reverse      TCTCAATGGTGTCACTGGGC
  NFKBIE-Forward     AAACTGGCAAGGTCTGGCTT
  NFKBIE-Reverse     GTCTTACCACTGGTGCCCTC
  GADD45A-Forward    GCAGAAGACCGAAAGCGACC
  GADD45A-Reverse    TGATGTCGTTCTCGCAGCAA

###### 

List of primary antibodies used for western blotting.

  Name                Supplier                                     Cat. no.
  ------------------- -------------------------------------------- ------------
  HDAC6               Beyotime Institute of Biotechnology          AH395
  α-tubulin (11H10)   Cell Signaling Technology, Inc.              2125S
  Ac-α-tubulin        Cell Signaling Technology, Inc.              5335S
  HSP90               Cell Signaling Technology, Inc.              4877T
  Ac-k                Cell Signaling Technology, Inc.              9441S
  Cleaved-parp        Cell Signaling Technology, Inc.              5625S
  Cleaved-caspase3    Cell Signaling Technology, Inc.              9664S
  CDK1                Absin                                        abs135544
  P-CDK1              Cell Signaling Technology, Inc.              2461T
  cyclin B1           Cell Signaling Technology, Inc.              4138S
  P-MLC               Invitrogen; Thermo Fisher Scientific, Inc.   PA5-17727
  MLC2                Cell Signaling Technology, Inc.              8505S
  YAP                 Cell Signaling Technology, Inc.              14074S
  P-YAP               Cell Signaling Technology, Inc.              13008T
  TEAD1               Cell Signaling Technology, Inc.              12292S
  TEAD2               ProteinTech Group, Inc.                      21159-1-AP
  TEAD3               Cell Signaling Technology, Inc.              13224S
  TEAD4               Abcam                                        ab58310

###### 

List of siRNAs used for siRNA transfection.

  Gene name         Sequence (5′-3′)
  ----------------- -----------------------
  TEAD1-homo-1018   CCACUGCCAUUCAUAACAATT
  TEAD1-homo-1826   CAUGGCCUGUGUGUUUGAAT
  TEAD2-homo-667    CCAGAUGUGAAGCCAUUCUTT
  TEAD2-homo-1283   GCGCCAGAUCUAUGACAAATT
  TEAD3-homo-1040   GCGCCAGAUCUAUGACAAATT
  TEAD3-homo-1510   CCCAGCACCAUGUCUACAATT
  TEAD4-homo-1284   CCACGAAGGUCUGCUCUUUTT
  TEAD4-homo-1507   GGAGACCUUGCUGUGCAUUTT
  NC                UUCUCCGAACGUGUCACGUTT

siRNA, small interfering RNA; TEAD, TEA domain family member; NC, negative control.
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